ONC (BeOne Medicines) Other Current Receivables: $10 Mil (As of Mar. 2026)


ONC BeOne Medicines Ltd ONC
79 GF Score
Price $302.83
GF Value $367.92
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BeOne Medicines Other Current Receivables?

BeOne Medicines ONC +0.31% 79 Other Current Receivables is $10 Mil as of Mar. 2026. GuruFocus rates ONC with a GF Score™ of 79/100 and a GF Value™ of $367.92 (Modestly Undervalued). The stock has 4 warning signs investors should review.

BeOne Medicines's Other Current Receivables for the quarter that ended in Mar. 2026 was $10 Mil.

BeOne Medicines's quarterly Other Current Receivables declined from Sep. 2025 ($39.10 Mil) to Dec. 2025 ($21.78 Mil) but then stayed the same from Dec. 2025 ($21.78 Mil) to Mar. 2026 ($10.35 Mil).

BeOne Medicines's annual Other Current Receivables declined from Dec. 2023 ($37.86 Mil) to Dec. 2024 ($32.83 Mil) and declined from Dec. 2024 ($32.83 Mil) to Dec. 2025 ($21.78 Mil).

BeOne Medicines Other Current Receivables Related Terms

BeOne Medicines Other Current Receivables Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Other Current Receivables Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.06 25.82 37.86 32.83 21.78

BeOne Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.74 109.35 39.10 21.78 10.35
ONC
79GF Score
BeOne Medicines Ltd ONC
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $10 Mil mean?
BeOne Medicines (ONC) has a Other Current Receivables of $10 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' Other Current Receivables too high?
BeOne Medicines' current Other Current Receivables is $10 Mil. Overall, BeOne Medicines has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Other Current Receivables compare to MRNA and RPRX?
BeOne Medicines' Other Current Receivables of $10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current Other Current Receivables is $10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $367.92, compared to a current price of $302.83 — trading 17.7% below its estimated fair value. The current Other Current Receivables is $10 Mil. BeOne Medicines' overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Other Current Receivables is $10 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (ONC) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $302.83 is trading 17.7% below its estimated GF Value™ of $367.92. GuruFocus considers BeOne Medicines to be Modestly Undervalued.

Key valuation signals for ONC:

  • Other Current Receivables: $10 Mil
  • GF Value™: $367.92 vs. price of $302.83 (17.7% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
79GF Score

Get the complete analysis for ONC

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$302.83
Price
$367.92
GF Value